Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.

Literature DB >> 19809593

PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.

Marcian E Van Dort¹, Alnawaz Rehemtulla, Brian D Ross.

Abstract

Spiraling drug developmental costs and lengthy time-to-market introduction are two critical challenges facing the pharmaceutical industry. The clinical trials success rate for oncology drugs is reported to be 5% as compared to other therapeutic categories (11%) with most failures often encountered late in the clinical development process. PET and SPECT nuclear imaging technologies could play an important role in facilitating the drug development process improving the speed, efficiency and cost of drug development. This review will focus on recent studies of PET and SPECT radioligands in oncology and their application in the investigation of tumor biology. The use of clinically-validated radioligands as imaging-based biomarkers in oncology could significantly impact new cancer therapeutic development.

Entities: Disease

Year: 2008 PMID： 19809593 PMCID： PMC2756754 DOI： 10.2174/157340908783769265

Source DB: PubMed Journal: Curr Comput Aided Drug Des ISSN： 1573-4099 Impact factor: 1.606

89 in total

1. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors: Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal: J Nucl Med Date: 2006-05 Impact factor: 10.057

2. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors: Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

3. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.

Authors: C J Anderson; F Dehdashti; P D Cutler; S W Schwarz; R Laforest; L A Bass; J S Lewis; D W McCarthy
Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057

Review 4. Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance.

Authors: Maarten F Corsten; Leonard Hofstra; Jagat Narula; Chris P M Reutelingsperger
Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701

5. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.

Authors: Morand Piert; Hans-Jürgen Machulla; Maria Picchio; Gerald Reischl; Sybille Ziegler; Piyush Kumar; Hans-Jürgen Wester; Roswitha Beck; Alexander J B McEwan; Leonard I Wiebe; Markus Schwaiger
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

6. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors.

Authors: Irina Velikyan; Asa Liljegren Sundberg; Orjan Lindhe; A Urban Höglund; Olof Eriksson; Eva Werner; Jorgen Carlsson; Mats Bergström; Bengt Långström; Vladimir Tolmachev
Journal: J Nucl Med Date: 2005-11 Impact factor: 10.057

Review 7. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction.

Authors: Y Sato; S Kanno; N Oda; M Abe; M Ito; K Shitara; M Shibuya
Journal: Ann N Y Acad Sci Date: 2000-05 Impact factor: 5.691

8. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors: Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal: J Pathol Date: 2003-07 Impact factor: 7.996

Review 9. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal: Eur J Nucl Med Date: 1993-08

Review 10. Multimodality imaging of tumor integrin alphavbeta3 expression.

Authors: Xiaoyuan Chen
Journal: Mini Rev Med Chem Date: 2006-02 Impact factor: 3.862

12 in total

1. Establishment of an mKate2-Expressing Cell Line for Non-Invasive Real-Time Breast Cancer In Vivo Imaging.

Authors: Ivan Vuletic; Jinghao Liu; Honglian Wu; Yichen Ding; Yu Lei; Changhui Li; Desheng Zhu; Qiushi Ren; Hongfang Sun; Jun Li
Journal: Mol Imaging Biol Date: 2015-12 Impact factor: 3.488

2. Validation of Bevacizumab Therapy Effect on Colon Cancer Subtypes by Using Whole Body Imaging in Mice.

Authors: Ivan Vuletic; Kedi Zhou; Hui Li; Huichen Bai; Xiangxi Meng; Sihao Zhu; Yichen Ding; Jun Li; Hongfang Sun; Qiushi Ren
Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488

Review 3. Near-infrared diffuse correlation spectroscopy in cancer diagnosis and therapy monitoring.

Authors: Guoqiang Yu
Journal: J Biomed Opt Date: 2012-01 Impact factor: 3.170

4. Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors: Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal: Nucl Med Biol Date: 2012-11-12 Impact factor: 2.408

Review 5. Biomarker selection and imaging design in cancer: A link with biochemical pathways for imminent engineering.

Authors: Joham Surfraz Ali; Noor Ul Ain; Sania Naz; Muhammad Zia
Journal: Heliyon Date: 2020-02-03

6. Therapeutic Efficiency of Multiple Applications of Magnetic Hyperthermia Technique in Glioblastoma Using Aminosilane Coated Iron Oxide Nanoparticles: In Vitro and In Vivo Study.

Authors: Gabriel N A Rego; Mariana P Nucci; Javier B Mamani; Fernando A Oliveira; Luciana C Marti; Igor S Filgueiras; João M Ferreira; Caroline C Real; Daniele de Paula Faria; Paloma L Espinha; Daianne M C Fantacini; Lucas E B Souza; Dimas T Covas; Carlos A Buchpiguel; Lionel F Gamarra
Journal: Int J Mol Sci Date: 2020-01-31 Impact factor: 5.923

Review 7. Hypoxia and the phenomenon of immune exclusion.

Authors: Violena Pietrobon; Francesco M Marincola
Journal: J Transl Med Date: 2021-01-06 Impact factor: 5.531

Review 8. Challenges and opportunities in the development of metal-based anticancer theranostic agents.

Authors: Shreyas P Vaidya; Shubhankar Gadre; Ravi Teja Kamisetti; Malay Patra
Journal: Biosci Rep Date: 2022-05-27 Impact factor: 3.840

9. Preclinical Evaluation of a Potential GSH Ester Based PET/SPECT Imaging Probe DT(GSHMe)₂ to Detect Gamma Glutamyl Transferase Over Expressing Tumors.

Authors: Harleen Khurana; Virendra Kumar Meena; Surbhi Prakash; Krishna Chuttani; Nidhi Chadha; Ambika Jaswal; Devinder Kumar Dhawan; Anil Kumar Mishra; Puja Panwar Hazari
Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240

10. Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model.

Authors: Siao-Syun Guan; Cheng-Tien Wu; Tse-Zung Liao; Tsai-Yueh Luo; Kun-Liang Lin; Shing-Hwa Liu
Journal: EJNMMI Res Date: 2020-02-24 Impact factor: 3.138